Kornimate/medical-research-clean huggingface dataset:
effectiveness of routine application of anterior approach during right hepatectomy

Conditions: Liver Neoplasm

Summary: the aim of this study was to evaluated the advantages of routine application of the anterior approach in patients scheduled to right hepatectomy or extended right hepatectomy, without infiltration of segment 1, inferior vena cava or main bile duct.

mobilization of the liver during right hepatectomy with classic approach is performed before parenchymal transection. in this phase severe bleeding may occur due to laceration of the inferior vena cava (ivc) wall, rupture or ligation falling off the hepatic short vein (hsv) or bleeding from the right liver attachments. besides, the twisting of the portal pedicle during mobilization can render the left hepatic lobe ischemic for transient interruption of the hepatopetal flow. these events are more frequent in case of large hepatic lesions (mainly hcc) that involves surrounding structures (such as diaphragm). two of the most important factors that affect the postoperative course of patients undergoing liver resections are indeed intraoperative bleeding and postoperative liver dysfunction. for these reasons lai et al proposed anterior approach as alternative to classic right hepatectomy. in this case liver mobilization is performed only at the end of parenchymal transection, when all vascular connections are already interrupted. liu et al published the results of a retrospective study in which 54 patients with, right sided hcc greater than 5 cm underwent right hepatectomy using the anterior approach technique. the anterior approach group had significantly less intraoperative blood loss, less need of blood transfusion and a lower hospital mortality rate. the same group reported results of a prospective randomized controlled study analyzing 120 patients with large (\>5 cm) right liver hcc. the overall operative blood loss, morbidity, and duration of hospital stay were comparable in both groups. however, a higher number of patients in classic approach group experienced mayor operative blood loss (\> 2000 cc) and required blood transfusions (8.3% vs. 28.3%).

Eligibility criteria:
inclusion criteria: * patients between 18 and 80 years * patients scheduled to right hepatectomy or extended right hepatectomy * the future remnant liver (frl) ≥ 25% in patients with a normal liver or ≥ 30% in those with chronic liver disease * indocyanine green retention rate (icg) at 15 minutes ≤ 10% in cirrhotic patients exclusion criteria: * resection of s1 * resection of bile duct * infiltration of inferior vena cava * america society of anesthesiologists (asa) grade iv * emergency surgery

Keywords: liver tumours
comparison of amikacin lung delivery with two nebulizers

Conditions: Healthy; Cystic Fibrosis

Summary: comparison between two modalities of nebulization.


Eligibility criteria:
inclusion criteria: * male healthy subjects * cystic fibrosis exclusion criteria: * kidney failure * no pregnancy

Keywords: healthy volunteers
effects of controlled ovarian hyperstimulation (coh) with letrozole and gonadotropin

Conditions: Infertility; Breast Cancer

Summary: fertility drugs have the effect of increasing hormone levels. higher hormone levels from infertility treatments may increase breast cancer risk, but there has not been enough research to know for sure. researchers want to use a method of taking breast tissue cells from women who are having infertility treatment. the breast tissue cells might show changes that would indicate an increased risk of cancer. the method of taking the breast tissue cells is called fine needle aspiration (fna). the purpose of this study is to examine the changes in breast tissue, in women at high risk of breast cancer who are being treated with controlled ovarian hyperstimulation.


Eligibility criteria:
inclusion criteria: 1. women must be at increased risk for breast cancer based on any of the following criteria: * age 30 or older with no prior live birth. * mutations associated with hereditary cancer (brca1 or 2, p53, pten) * family history of breast cancer including one first degree or multiple second degree relatives * history of chest radiation before age 30 * multiple prior breast biopsies * precancerous conditions (dcis, lcis, ah) * prior history of breast or ovarian cancer * estimated mammographic breast density \> 50% 2. must be undergoing infertility treatment at the university of kansas with controlled ovarian hyper-stimulation (coh) 3. must be between the ages of 21-45 (both inclusive) with day 3 fsh less than 12 iu/l, day 3 e2 less than 80 pg/ml exclusion criteria: 1. women under 21 or over 45 years old 2. day 3 fsh over 12 iu/l, day 3 e2 over 80 pg/ml 3. women who do not meet risk criteria above 4. history of hypersensitivity to letrozole or gonadotropin 5. uterine and adnexal pathology 6. use of clomid or gonadotropin within 30days before the letrozole cycle 7. any severe chronic disease of relevance for reproductive function

Keywords: fertility high risk, controlled ovarian stimulation, breast cancer
effect of cocoa supplementation in training athletes microbiota and metabolome

Conditions: Healthy Athletes

Summary: it has recently been suggested that cocoa may improve exercise performance and recovery. this study aim to evaluate the plasma and fecal metabolome after 10 weeks of cocoa supplementation during the training period in recreational athletes to detect possible metabolites involved in the observed benefits of cocoa in athletes


Eligibility criteria:
inclusion criteria: * 18-45 years of age * high physical condition (vo2 ≥ 55 ml/kg/min) * bmi 18-25 kg/m2 exclusion criteria: * antibiotics intake during 3 months prior to the study, * smoking * nutritional complements * ergogenic complements * prebiotics * probiotics * vegetarian or vegan diet * chronic medication * gastrointestinal surgery * any diagnosed disease
influence of beta blockers on prognosis in patients with acute myocardial infarction complicated with normal ejection fraction

Conditions: AMI

Summary: to understand the effect of beta blockers on the prognosis of patients with acute myocardial infarction with preserved ejection fraction.

the use of beta blockers is an important component of drug therapy for myocardial infarction, but in some exceptional cases, evidence-based evidence for their use is insufficient, and we seek to understand the prognostic impact of beta blockers on patients enrolled in long-term follow-up.

Eligibility criteria:
inclusion criteria: * patients with acute myocardial infarction exclusion criteria: * previous history of heart failure admission killip class \> i class cancer pregnant
comparison of palonosetron and ramosetron for preventing patient-controlled analgesia related nausea and vomiting following spine surgery; association with abcb1 polymorphism

Conditions: Postoperative Nausea and Vomiting

Summary: opioid-based intravenous patient-controlled analgesia (iv-pca) offers excellent pain control, however, its use inevitably increases the incidence of postoperative nausea and vomiting (ponv). ramosetron and palonosetron are commonly used 5-ht3 antagonists for the prevention and treatment of ponv. it is not clear which one has superior antiemetic efficacy for the prevention of ponv in patients using opioid-based iv-pca. the antiemetic efficacy of 5ht3 antagonists may be influenced by polymorphism of abcb1, a drug-transporter gene. this study evaluates relative antiemetic efficacy of ramosetron and palonosetron in patients using iv-pca after spinal surgery and impact of abcb1 polymorphism on the antiemetic efficacy of the ramosetron and palonosetron. the incidence and intensity of ponv during postoperative 48 h will be assessed. abcb1 polymorphisms 3435c\>t and 2677g\>t/a will be evaluated in all patients.


Eligibility criteria:
inclusion criteria: * patients aged 20-85 yr * undergoing spine surgery exclusion criteria: * taking steroids or opioids preoperatively * gi motility disorder * uncontrolled diabetes * severe renal or hepatic disease * transfer to icu postoperatively * obesity (bmi\>35 kg/m2) * use of antiemetic agent within 24 h preoperatively * pregnancy * psychiatric disease * drug or alcohol abuser * malignancy
aqueous suppressant versus aqueous outflow on ocular blood flow

Conditions: Glaucoma

Summary: the purpose of this study will be to compare the aqueous production suppressant to aqueous outflow drugs in terms of the response to known vascular parameters. specifically; systemic perfusion pressure, retrobulbar blood flow and retinal microcirculation.

the purpose of this study will be to compare the aqueous production suppressant to aqueous outflow drugs in terms of the response to known vascular parameters. specifically; systemic perfusion pressure, retrobulbar blood flow and retinal microcirculation. a comparison of perfusion pressure, retinal microcirculation utilizing heidelberg retinal flowmetry and retrobulbar circulation utilizing color doppler ultrasound imaging

Eligibility criteria:
inclusion criteria: patients will meet all of the following inclusion criteria to enter the study: 1. age: 30 years or older. 2. diagnosis: confirmed open-angle glaucoma in at least one eye: 1. glaucomatous visual field loss on humphrey 24-2 or 10-2 perimetry 2. glaucomatous optic disc cupping 3. agreement between two baseline exams for reliability 3. best corrected visual acuity at least 20/60 in at least one eye. 4. prior humphrey visual fields demonstrate acceptable reliability standards (see below). exclusion criteria: 1. extensive humphrey visual field damage consisting of either a mean deviation (md) \< -15 decibels or a clinically determined threat to fixation in both hemifields. 2. evidence of exfoliation or pigment dispersion. 3. history of acute angle-closure or a narrow, occludable anterior chamber angle by gonioscopy. 4. history of chronic or recurrent inflammatory eye diseases (e.g., scleritis, uveitis). 5. history or signs of intraocular trauma. 6. severe or potentially progressive retinal disease such as retinal degeneration, diabetic retinopathy, and retinal detachment. 7. any abnormality preventing reliable applanation tonometry. 8. current use of any ophthalmic or systemic steroid which may interfere with this investigation. 9. cataract surgery within the past year. 10. resting pulse \< 50 beats per minute. 11. severe, unstable or uncontrolled cardiovascular, renal, or pulmonary disease.

Keywords: glaucoma blood flow
the effect of vibration therapy on the bone density of the tiba in patients with spinal cord injury

Conditions: Spinal Cord Injury

Summary: the purpose of this investigation is to determine the effect of lower limb vibration therapy on bone density in the tibia in patients with spinal cord injury. the second purpose is to assess the neuromuscular junction variability at the motor units of the tibialis anterior muscle after a sequence of lower limb vibration therapy


Eligibility criteria:
inclusion criteria: * over the age of 18 years * a spinal cord injury patient with injury above t12 * injury below t4 to avoid respiratory complication. * an asia classification of a or b exclusion criteria: * non complicating organic factors such as heart disease, high blood pressure, stroke * exercise where electrical therapy is used while the trial is being conducted * a bone density measure 3 times below normal mineralization levels as measured on the first bone density scan prior to entry in to the study * surgical implants below the level of t12 * local infection, acute inflammation, injury, tumors or other malignancy, recent wounds, diabetes * any unstable joints of the lower extremity, recent hip and knee joints or fitted hip or knee pins, bolts and/or plates * acute thrombosis * severe migraine, epilepsy * serious cardiovascular disease, wearing a pacemaker * any spinal manipulation within one year of the study * any implanted device or prosthesis or intrauterine iud type of device pregnancy

Keywords: spinal cord injury vibration therapy bone density
incidence, risk factor, treatment and overall survival of locoregionally recurrent colon cancer

Conditions: Colonic Neoplasms; Neoplasm Recurrence, Local

Summary: data on disease recurrence was collected for all primary colon cancer patients diagnosed in the netherlands over the first six months of 2015. three-year cumulative incidence, risk factors, treatment and three-year os of locoregionally recurrent colon cancer were determined.


Eligibility criteria:
inclusion criteria: * histologically confirmed stage i-iii primary colon carcinoma; * diagnosed between january 1st and june 30th of 2015; * surgical resection of primary colon carcinoma. exclusion criteria: * appendiceal localization; * neuroendocrine tumor morphology;
group-based intervention for club patrons

Conditions: Drink Too Much; Drinking, Binge; Drunk; Drug Use; Aggression; Aggression Sexual; Peer Group; Safety Issues; Harm Reduction

Summary: the purpose of this study is to develop and test a group-based strategy for encouraging groups of young adults who are engaged in party behaviors at nightclubs to intervene with each other to reduce harms associated with overuse of alcohol and recreational drugs and to reduce harms associated with aggression (physical and sexual).

this study focuses on high risk behaviors (excessive alcohol use, drug use) and unwanted experiences (physical/sexual aggression) that may occur during an evening at a night club for young adults engaged in party behaviors. the goals were: 1) to develop a screener that accurately assesses a group's level of risk for one specific night of club attendance and based upon this assessment, (2) to provide naturally occurring social groups with the necessary skills to identify vulnerability for and to provide them with tools to reduce harms. an algorithm calculated in real time during an entrance survey predicted the types of risks that the group members may encounter during the evening based upon past behaviors and expectations for the evening. social groups in the experimental condition were exposed to a brief intervention that focused on developing skills described as the 3 o's: a) outreach-how to approach fellow group members who are at risk, (b) options-how to suggest options that would increase safety and (c) out-how to assess when it is time to leave the club. this brief, interactive intervention was delivered by small tablet computers that utilized mobile application technology and cellular wireless service. this low cost delivery was considered important to providing later adoption in the real world and the interactive nature of the intervention was designed to appeal to the young adult population.

Eligibility criteria:
inclusion criteria: * must be within age range, entering the club that night, group size must be 2 or more exclusion criteria: * working or performing at the club that night

Keywords: nightclubs bars alcohol drugs aggression harm reduction
electronic iief validation

Conditions: Erectile Dysfunction

Summary: questionnaires are used within urology to objectify disease burden and symptom changes during therapy. recent technological improvements, as the smartphone and tablet, create new fill-out possibilities. however, questionnaires are only validated on paper. in order to use questionnaires for multiple platforms, electronic validation is needed. the international prostate symptom score has already been validated on the smartphone. the international index of erectile function (normal version of 15 questions and short version of 5 questions) is widely used within urology, however electronic validation is required for usage on electronic platforms in the future.


Eligibility criteria:
inclusion criteria: * male patients, ≥40 years of age, presenting at the outpatient clinic of urology of the academic medical center in amsterdam. * in possession of a smartphone, tablet or laptop/computer with internet connection. * access to email. * fluent speaking and reading the dutch language. exclusion criteria: * change in treatment, especially erectile dysfunction at consultation which could impact the short term iief outcome during the cross-over time. * unable to provide informed consent. * unfit according to the medical doctor (for example cognitive problems, leading to inadequate follow-up of instructions).

Keywords: iief electronic validation
bacteriophage therapy for difficult-to-treat infections: the implementation of a multidisciplinary phage task force

Conditions: Musculoskeletal Infection; Chronic Rhinosinusitis (Diagnosis); Sepsis; Pulmonary Infection; Hidradenitis Suppurativa

Summary: phageforce is a prospective, observational registry study. the university hospitals leuven has approved the application of phage therapy as standard-of-care only in patients for whom no curative treatment alternatives (antibiotic and/or surgical) are available ('last-resort cases'). a multidisciplinary phage task force, referred to as the coordination group for bacteriophage therapy leuven (cbl) was set up. the cbl screens patients with difficult-to-treat infections, evaluates who could benefit from phage therapy and sets up the treatment protocol. with this study, the cbl aims to gain insight in the safety and efficacy of phage therapy by integrating and optimizing phage therapy in five distinct medical disciplines (with distinct routes of administration), facilitating long-term follow-up of patients. furthermore, this study will gain insight in the biodistribution and exact mechanisms of action of phage therapy and thus be able to provide standardized guidelines for each patient population and route of administration.

patients with difficult-to-treat musculoskeletal infections, chronic rhinosinusitis, sepsis, pulmonary infections associated with cystic fibrosis or bronchiectasis, or hidradenitis suppurativa, for whom no standard (curative) treatment options are available, are eligible for phage therapy. patient eligibility is evaluated by the coordination group for bacteriophage therapy leuven. if phages are available against the isolated bacterial species and the patient is found eligible for phage therapy, a phagogram is performed. solely based on the results of the phagogram, the patient is either included in the phage treated or control group (standard (non-curative) treatment). in both cases, data is collected using redcap.

Eligibility criteria:
inclusion criteria: all patients: * diagnosed with a musculoskeletal infection or chronic rhinosinusitis or sepsis or lung infection (cf/bx) or hidradenitis suppurativa, and * for whom all previous treatments (surgical and antibiotic) have failed or for whom no other treatment options are available (i.e., last resort cases, based on the assessment of the cbl), for example in case of bacterial resistance. and * of whom the pathogen causative for the infection is one for which phages are available in the phage bank, and * who have given informed consent to have their data collected in a patient registry exclusion criteria: all patients: * with an infectious disease other than those mentioned above, and/or * for whom standard treatment alternatives are still available. and/or * of whom the pathogen causative for the infection is not one for which phages are available in the phage bank. and/or * who refused to give their informed consent

Keywords: bacteriophage therapy personalized treatment difficult-to-treat infection
omega 3 in les and aps

Conditions: Systemic Lupus Erythematosus; Primary Antiphospholipid Syndrome

Summary: it has been demonstrated that epa and dha supplementation may have anti-inflammatory properties in several chronic diseases, namely, diabetes, obesity, and in rheumatoid arthritis, although not with controversy. systemic lupus erythematosus (sle) and antiphospholipid antibody syndrome (aas) are autoimmune diseases characterized by a chronic inflammatory state which is associated with the disease´s clinical symptoms. thus, we hypothesized that epa and dha supplementation may beneficially affect the inflammatory cytokine profile and clinical features of les and aas patients.


Eligibility criteria:
inclusion criteria: • age between 7 and 40 years exclusion criteria: * cardiovascular dysfunction * rhythm and conduction disorders * musculoskeletal disturbances * kidney and pulmonary involvements * peripheral neuropathy * use of tobacco * treatment with lipid-lowering or hypoglycemic drugs * fibromyalgia * use of chronotropic or antihypertensive drugs * physically active subjects
safety and efficacy of hmi-103 in participants with classical pku due to pah deficiency

Conditions: Phenylketonurias; PAH Deficiency; Phenylketonuria

Summary: this is an open-label, sequential ascending dose-escalation, phase 1 study to evaluate the safety and efficacy of a single intravenous (i.v.) administration of hmi-103, a gene editing development candidate, in adult participants aged 18 to 55 years, inclusive, with classical pku due to pah deficiency who have uncontrolled disease despite phe restricted dietary management.

this is an open-label, sequential ascending dose-escalation, phase 1 study to evaluate the safety and efficacy of a single intravenous administration of hmi-103, a gene editing development candidate, in adult participants aged 18 to 55 years, inclusive, with classical pku due to pah deficiency who have uncontrolled disease despite phe-restricted dietary management. up to 3 dose levels of hmi-103 may be investigated. at a given dose level, 3 participants are planned to be enrolled and dosed. participant dosing will be staggered.

Eligibility criteria:
inclusion criteria: * adults 18-55 years of age at the time of informed consent * diagnosis of classical phenylketonuria (pku) due to pah deficiency * four baseline plasma phe values with a concentration of ≥ 600 μmol/l and at least one historical value ≥ 600 μmol/l in the preceding 24 months. * participants must have uncontrolled classical pku disease (despite phe-restricted dietary management) in the judgment of the investigator and confirmed by the independent dmc at the end of the screening period. * participant has the ability and willingness to maintain their baseline diet, for the duration of the trial, unless otherwise directed exclusion criteria: * subjects with pku that is not due to pah deficiency * presence of anti-aavhsc15 neutralizing antibodies * participants who are well controlled on a phe-restricted diet. * hemoglobin a1c \>6.5% or fasting glucose \>126 mg/dl * liver function tests \> uln * international normalized ratio (inr) \> 1.2 * hematology values outside of the normal range * previously received gene therapy for the treatment of any condition.

Keywords: pku gene editing aavhsc
manual lymphatic drainage in women undergone to thigh lifting

Conditions: Lymphedema; Obesity

Summary: this study will investigate the subcutaneous tissue changes in the lymphedema found after thigh surgery, by circumferential measure of thr thighs and by magnetic resonance imaging verifying the effects of postoperative lymphatic drainage.

patients will be invited to participate in the study, divided into two groups, and randomized to treatment by wwww.randomization.com, where 10 patients will participate in the study group(20 legs) and 10 control group patients(20 legs). total of 40 legs. then, the evaluation will be performed on preoperative time, consisting of physical examination and circumferential measures. others measurements will be taken im postoperative time and confirmed by magnetic resonance.

Eligibility criteria:
inclusion criteria: * female patients * age between 30 and 60 years old * bariatric surgery capella previous type * stabilization of weight loss for 1 year or more * patients with a body mass index less than or equal to 30 kg/m2 exclusion criteria: * pregnancy, childbirth or breastfeeding for less than 1 year * presence of uncontrolled systemic disease * other disease that require surgical interventions * lymphatic or venous pathologies in advance * patients over 110 kg * patients with a body mass index(bmi) greater than 30 kg/m2 * patients who has undergone plastic surgery of the thighs

Keywords: lymphedema magnetic resonance imaging plastic surgery